Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
GTC Biotherapeutics, Inc., an LFB Group Company, Announces Name Change to rEVO Biologics and Renewed Commitment to Evolving Recombinant Medicine

FRAMINGHAM, Mass., Jan. 3, 2013 /PRNewswire/ -- GTC Biotherapeutics announced today that it has changed its name to rEVO Biologics. The name change reflects the recent commercial growth of the company, and better aligns with the company's business strategy of evolving recombinant medicine for the treatment of rare diseases.

(Logo:  http://photos.prnewswire.com/prnh/20130103/NE36742LOGO )

"Our company is taking a revolutionary approach to the development of recombinant therapies, as evidenced by our lead product ATryn® Antithrombin (Recombinant) and its remarkable growth over the past year," stated rEVO Biologics President Yann Echelard, Ph.D. "With this change, our name now reflects that core strength. Our rPRO Technology enables us to maintain all of the advantages that recombinant science offers, but through an entirely different approach. The result is better efficiency, better scalability, better cost control and ultimately better patient access to these innovative therapies."

ATryn® Antithrombin (Recombinant) is the first and only recombinant antithrombin concentrate, and is currently the fastest-growing antithrombin product with market share that has tripled in the last 12 months.

The original GTC Biotherapeutics name dates back to when the company was Genzyme Transgenics Corporation, and a spinoff of Genzyme Corporation. Today, the company is a subsidiary of LFB Biotechnologies S.A., a leading European-based biopharmaceutical group. rEVO Biologics corporate offices are in Framingham, MA, with protein production facilities in Charlton, MA.

About rEVO Biologics
rEVO Biologics is a rare disease company focused on developing and delivering first- and next-generation therapeutics that are more cost effective to produce than traditional recombinant therapies. Through its proprietary rPRO Technology platform -- a scalable, transgenic, and cost-effective method of protein production -- rEVO Biologics is bringing safe and reliable therapeutic proteins to address critical medical needs. The company's lead product, ATryn® Antithrombin (Recombinant), is the first and only plasma-free antithrombin concentrate. ATryn received FDA approval in 2009. The company has a number of products in its pipeline and in clinical trials in the areas of hematology, oncology, genetic disorders and autoimmune disease, and is actively seeking additional indications for its lead product.

About LFB
LFB Biotechnologies S.A. is a wholly-owned subsidiary of LFB S.A, a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, including Hemostasis, Immunology and Intensive Care. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of new-generation medicinal products based on biotechnologies. The LFB Group is pursuing a growth strategy that seeks to extend its activities at the international level and develop innovative therapies. To that end, the LFB Group currently markets its products in 20 countries around the world with a global turnover of euro 432 millions in 2011.

CONTACT: Holly Grimshaw
508.620.9700

SOURCE rEVO Biologics

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
In high-production environments where release cycles are measured in hours or minutes — not days or weeks — there's little room for mistakes and no room for confusion. Everyone has to understand what's happening, in real time, and have the means to do whatever is necessary to kee...
"Our premise is Docker is not enough. That's not a bad thing - we actually love Docker. At ActiveState all our products are based on open source technology and Docker is an up-and-coming piece of open source technology," explained Bart Copeland, President & CEO of ActiveState Sof...
ScriptRock makes GuardRail, a DevOps-ready platform for configuration monitoring. Realizing we were spending way too much time digging up, cataloguing, and tracking machine configurations, we began writing our own scripts and tools to handle what is normally an enormous chore...
The Internet of Things is not new. Historically, smart businesses have used its basic concept of leveraging data to drive better decision making and have capitalized on those insights to realize additional revenue opportunities. So, what has changed to make the Internet of Things...
SYS-CON Media announced today that Sematext launched a popular blog feed on DevOps Journal with over 6,000 story reads over the weekend. DevOps Journal is focused on this critical enterprise IT topic in the world of cloud computing. DevOps Journal brings valuable information t...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE